Enrichment of circulating head and neck tumour cells using spiral microfluidic technology by Kulasinghe, Arutha Jeevana et al.
1Scientific RepoRts | 7:42517 | DOI: 10.1038/srep42517
www.nature.com/scientificreports
Enrichment of circulating head 
and neck tumour cells using spiral 
microfluidic technology
Arutha Kulasinghe1,2, Thao Huynh Phuoc Tran1, Tony Blick1,2, Ken O’Byrne1,2,3, 
Erik W. Thompson1,2,4, Majid E. Warkiani5, Colleen Nelson1,2,6, Liz Kenny7 & 
Chamindie Punyadeera1,2
Whilst locoregional control of head and neck cancers (HNCs) has improved over the last four decades, 
long-term survival has remained largely unchanged. A possible reason for this is that the rate of distant 
metastasis has not changed. Such disseminated disease is reflected in measurable levels of cancer 
cells in the blood of HNC patients, referred to as circulating tumour cells (CTCs). Numerous marker-
independent techniques have been developed for CTC isolation and detection. Recently, microfluidics-
based platforms have come to the fore to avoid molecular bias. In this pilot, proof of concept study, we 
evaluated the use of the spiral microfluidic chip for CTC enrichment and subsequent detection in HNC 
patients. CTCs were detected in 13/24 (54%) HNC patients, representing both early to late stages of 
disease. Importantly, in 7/13 CTC-positive patients, CTC clusters were observed. This is the first study to 
use spiral microfluidics technology for CTC enrichment in HNC.
Head and neck cancers (HNCs) account for the 7th most common tumour type globally. Whilst there have been 
improvements in locoregional control of HNC, distant metastasis remains a challenge1. Circulating tumour cells 
(CTCs), are rare cancer cells shed into circulation, representing metastatic seeds and providing a window into 
metastasis. CTCs have the potential to provide critical information on the metastatic cascade, tumour heteroge-
neity and chemoresistance2–5. Whilst CTCs have been well studied in metastatic breast, prostate and colorectal 
cancer patients3,6, the HNC CTC field remains in its infancy1,7–9. Epidermal growth factor receptor (EGFR), which 
has been shown to be amplified in HPV-negative tumours compared to HPV-positive tumours, has previously 
been characterized in HNC CTCs7,9–14.
CTCs, when present, are extremely rare in comparison to the plethora of white blood cells in circulation15. 
The CellSearch system (Janssen Diagnostics) has FDA-approval for CTC enumeration in a number of tumour 
types and has been used to demonstrate the clinical relevance of EpCAM-positive CTCs6. This system has been 
robust in CTC enumeration through marker based CTC capture6,16. Numerous marker-based assays using micro-
fluidic technologies are available and have been previously reported17,18. However, it has been shown that affin-
ity based platforms have limitations due to poor sensitivity19,20. This is further compounded by varying levels 
of cell surface marker expression, CTC heterogeneity and specific processes such as epithelial-to-mesenchymal 
transition (EMT)1,21,22. The current view is that CTCs can show an intermediate EMT phenotype2,20,23 as well as 
express varying degrees of other markers such as PD-L1, CXCR4 and Plastin-32,24. Based on the heterogeneity 
found among CTCs, compounded with sometimes low-EpCAM expression, critical subpopulations may not be 
detected. Therefore, various marker-independent CTC enrichment strategies need to be tailored for each tumour 
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type18–20. Marker-independent enrichment relies on the physical properties of CTCs such as size, deformability, 
charge and density1,15,19,25,26.
Recently, there has been a demand in the field for the isolation of viable CTCs on which to perform functional 
assays. There has been a shift toward methodologies that allow for (i) marker-independent CTC capture (ii) CTC 
propagation (iii) minimal pre-enrichment processing and (iv) processing larger volumes of blood in a short time 
period1,2,27–29. To encompass the above, the spiral microfluidics technology developed by Warkiani et al.15,27,30–32. 
was evaluated. The spiral chip is a marker-independent and high-throughput device that utilises hydrodynamic 
forces present in curvilinear microchannels for size-based cell sorting15,27. The spiral chip has previously been 
reported for use in breast and lung cancers32. CTC separation from lysed whole blood occurs based on CTC 
deformability and size. In this study, we enriched blood from 24 HNC patients using the spiral microfluidics 
platform and enumerated CTCs using immunocytochemistry. Our evaluation is the first study using the spiral 
technology for CTC enrichment from patients with HNCs, and shows positive results. Future, multi-centre trials 
are required and warranted before this technology can be implemented in a clinical setting.
Results
Spiral Chip enrichment. The spiral chip utilizes the inherent Dean vortex flows present in curvilinear 
microchannels under continuous flow, along with inertial lift forces, which focus the CTCs near the microchannel 
inner wall while driving the smaller hematologic cells toward the microchannel outer wall, allowing an efficient 
separation at the outlet (Fig. 1). The cells are separated as a function of deformability and size, as cells occupy 
different lateral positions away from the walls of the microchannel, allowing for separation at the bifurcation 
position27. Typically, cells larger than 14 μ m flow into the “CTC outlet” and cells smaller than this size flow into 
the “waste outlet.”
Recovery Studies. FaDu, CAL27, RPMI2650 and MDA-MB-468 cell line cells, which all have a mean diam-
eter above 15 μ m (Fig. 2), were used for spike-in experiments. The percentage recovery of spiked-in cells (Fig. 3i) 
ranged from 60–70% when experiments were performed with 100–150 cells spiked into 10 mL blood, trending 
to lower recover rates (40–60%) when less cells were spiked in. The overall recovery of the spiked cell lines were 
comparable to each other. We also assessed the decrease in background leukocytes and recovery of cancer cells 
after repeat passages through the spiral chip. When the samples were collected from the “CTC outlet” and run 
through the chip again, a 30% decrease in leukocytes was observed, however there was a 10–15% decrease in 
cancer cell recovery which was accounted for in the dead volumes of the setup. More than 1 repeat run did 
Figure 1. Spiral microfluidic chip setup. 
Figure 2. The mean diameter and standard deviation of 5 human cell lines and normal human 
lymphocytes. 
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not further purify the sample. Single cells and cell clusters were able to be enriched by the spiral chip (Fig. 3ii). 
Similarly, bioreactor-cultured spheroids could also be enriched by the spiral chip (Fig. 4).
Patient Characteristics. A total of 24 patients and 8 normal healthy controls were included in this study. 
Patient characteristics are shown in Table 1. The median age was 62 years (range 36–89); including men (n = 22), 
women (n = 2). The most distinctive histology was mucosal oral cavity SCC (63%). The majority of patients pre-
sented with tumour grading T2/T3 (71%) and either no nodal spread N0 (50%) or advanced nodal spread N2a-c 
(50%). Patients were assessed for distant metastases by CT/PET-CT and MRI scans. All patients were found to be 
radiographically M0 upon assessment. CTC status was determined at the same time point. The clinicopathologi-
cal patient findings are presented in Table 2.
Enrichment of CTCs from controls and patients. 10 mL blood samples were obtained from 8 healthy 
volunteers and 24 head and neck cancer patients and processed using the spiral chip. All samples were enu-
merated for CTCs. Putative CTCs were identified on the stained cytospots as positive for: pan-CK, DAPI and 
negative for CD45. Further characterisation of head and neck CTCs was performed by EGFR ICC and DNA 
FISH. Leukocytes were identified as positive for CD45, DAPI and negative for pan-CK. No CTC-like events 
were observed in the 8 normal healthy volunteers (Fig. 5). CTCs were detected in 13/24 (54%) (Range 1–12 
CTCs/10 ml blood sample) of the HNC patients screened in the study. CTC clusters were readily detectable in 
7/13 (53.8%) of the CTC-positive patients (Fig. 6). The CTCs were further molecularly characterised and found to 
have EGFR gene amplifications (Fig. 7). Further observations made in the patient samples include double positive 
pan-CK and CD45 cells in 2/20 samples and 27 CK-negative, CD45-negative cells in 1 patient presenting with a 
CTC cluster. These events were not considered for enumeration in the study.
Discussion
HNC patients often present with advanced metastatic spread, predominantly to the lungs, liver and bone1,33. The 
ability to assess “intact” metastatic precursors in the form of tumour cells in blood holds remarkable potential 
as a liquid biopsy. The number of CTCs, and molecular and genetic changes in the CTCs could be monitored 
Figure 3. (i) The mean % recovery and standard deviation for spiked cell lines (n = 3). (ii, a) Presentation 
of spike-in and recovered tumour cells FaDu cells into blood of a normal healthy volunteer. Tumour cells: 
cytokeratin (red), DAPI (blue) White blood cells: CD45 (green), DAPI (blue). Scale bar represents 10 μ m (b) 
RFP-labelled tumour cells from whole blood. Scale bar represents 50 μ m.
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in patients following therapy and non-responders determined at an earlier time point4,34,35. Moreover, patients 
whose disease will potentially respond to specific therapies could be identified. Recent studies have shown that 
PD-L1 is frequently expressed on CTCs and that these are present in patients where anti-PDL1 therapies could 
be effective24,36,37. Numerous CTC enrichment platforms have been developed in recent years, each with its own 
advantages and limitations1,21,38–40. In this study, we tested and evaluated the spiral microfluidics chip for CTC 
enumeration and characterization. This platform has features which are of value to clinical research; CTCs are 
found in suspension and not immobilized allowing for functional assays and CTC clusters can be readily isolated 
with a leukocyte depletion of up to 4 log15. Limitations of the spiral technology are that “small CTCs” or CTCs 
( < 12 μ m) in size will be lost15,41.
Four cell lines representing a mean cell diameter range between 16–28 μ m were chosen for the spiking exper-
iments to get a decent coverage of known head and neck cancer cells. In our hands, the percentage recovery of 
the spiral chip is similar to that of other microfluidic CTC isolation platforms19,21. By repeat passages of the spiral 
chip, a decrease of 30% background leukocytes was found at the expense of 10–15% recovery. However, repeated 
passages were not performed with patient samples so as not to risk losing CTCs. The range of detected CTCs in 
HNC patients remains low1,13,42,43. Moreover, it was observed that the same population of leukocytes was present 
after 2 or more repeat runs and this could not be further purified. Furthermore, the spiral chip successfully sorted 
for cell clusters and tumour spheroids in the CTC outlet.
Figure 4. Day 24, Bioreactor grown (A) FaDu spheroid (B) MDA-MD-468 (cell cluster). (C) MDA-MD-468 
Spiral sorted single and cell clusters (D) 600x image of Spiral sorted cell cluster. Scale bar represents 10 μ m.
Variables N
Total 24 (100%)
Gender
 Male 22 (91.7%)
 Female 2 (8.3%)
Age, y
 < 60 7
 > 60 17
Anatomic site of primary
 Oral Cavity 15
 Oropharyngeal 9
Tumour Size
 T1 3
 T2 10
 T3 7
 T4 4
Nodal spread
 N0 12
 N1 0
 N2a-c 12
Distant metastases
 M0 24
 M1 0
HPV status
 HPV-positive 12
 HPV-negative 12
CTC status
 CTC-positive 13 (Range from 1–12 CTCs/10 ml whole blood)
 CTC-negative 11
Table 1.  Patient demographics (n = 24).
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This pilot study evaluated the use of a spiral chip for CTC enrichment in HNCs. HNC patients ranged from 
early stage (T1N0M0) to advanced stage patients (T4N2b). Patients with early stage disease present with low rates 
of distant metastasis and a favourable prognosis. Whilst patients with locally advanced disease are more likely 
to have CTCs44. CTCs were observed in 50% of the HNC samples, ranging from 1–12CTCs/10 mL sample. This 
finding is consistent with previously published studies using marker-independent enrichment platforms7,13,45. 
Notably, post spiral enrichment involves transferring rare cells onto a glass slide and immunocytochemistry 
which can lead to cell loses34. Therefore, the actual CTC count per HNC patient could be much higher.
Patient Gender Age HPV status
T 
Staging
N 
Staging Description Lung findings
CTC 
findings CTC description
Micro_01 m 66 positive T2 N0 Oral Cavity lesion, query Positive 1 CTC cluster ~ 12cells
Micro_02 m 54 unknown T1 N0 Oropharyngeal Negative
Micro_03 m 63 negative T4 N2c Oropharyngeal lesion, query Positive 1 CTC
Micro_04 m 58 positive T3 N2b Oropharyngeal Negative
Micro_05 m 62 Positive T2 N2c Oropharyngeal Negative
Micro_06 m 42 negative T3 N2 Oral Cavity Positive
1 CTC cluster ~5 
cells, 27 nucleated 
single cells
Micro_07 f 72 unknown T1 N0 Oral Cavity Negative
Micro_08 m 48 unknown T1 N0 Oral Cavity Negative
Micro_09 m 63 positive T3 N2c Oral Cavity Positive 1 CTC cluster ~ 6 cells
Micro_10 m 61 positive T2 N0 Oral Cavity Negative
Micro_11 m 73 unknown T2 N0 Oral Cavity Positive 1 CTC cluster ~ 5 cells
Micro_12 m 36 negative T4 N2b Oral Cavity lesion, query Positive 3 CTCs
Micro_13 m 56 positive T2 N2b Oropharyngeal Positive 2 CTCs
Micro_14 f 55 positive T4 N2b Oropharyngeal Positive 1 CTC
Micro_15 m 71 negative T2 N0 Oral Cavity Negative
Micro_16 m 65 negative T3 N2b Oral Cavity Positive
1 cluster ~ 5 
cells + 2 single 
cells
Micro_17 m 60 Positive T3 N2b Oropharyngeal Positive
1 cluster ~7 
cells + 4 single 
cells
Micro_18 m 67 positive T3 N0 Oral Cavity Negative
Micro_19 m 60 positive T2 N2b Oropharyngeal Negative
Micro_20 m 68 positive T4 N0 Oral Cavity Negative 6 CTCs
Micro_21 m 62 negative T2 N0 Oropharyngeal Negative
Micro_22 m 68 negative T3 N2b Oral cavity Positive 2 CTCs
Micro_23 m 89 negative T2 N0 Oral Cavity Negative
Micro_24 m 60 negative T2 No Oral Cavity Positive 3 CTCs
Table 2.  Clinicopathological findings including CTC status and Lung findings.
Figure 5. Box plot summary indicating the range of CTCs (pan-CK + CD45-DAPI + ) cells/10 ml. The box 
plot presents the median and all individual data points. NHV; normal healthy volunteers.
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Over half of the CTC positive patients presented with clusters of cancer cells. These multicellular CTC clusters 
have shown 23–50 fold increased metastatic potential compared to single CTCs in breast cancers and associa-
tions with adverse clinical outcomes1,46–49, however the clinical significance in HNC is yet to be determined1,50–52. 
Moreover, these cell clusters have been reported to have a shorter circulation half-life in blood, consistent with 
rapid entrapment within the capillaries of distant organs46. Initial studies have shown that CTC clusters are 
potent initiators of distant organ metastasis, highlighting the need to develop strategies which disrupt cell-cell or 
cell-matrix adhesions in these clusters to reduce metastatic potential53. Further investigation is required to deter-
mine the clinical implications of CTC clusters in HNC patients. Importantly, CTCs were found upon presenta-
tion to clinic in 3/3 patients presenting with queried lung lesions by the MDT clinic (Fig. 8). These lung lesions 
were to be investigated by ultrasound guided fine-needle biopsy to determine the extent of distant metastasis. 
In these patients, a window for treatment escalation could become a possibility if the presence of CTCs predicts 
for patients at-risk of developing metastasis. Further studies assessing CTCs during the course of treatment and 
timing of blood sampling are warranted to investigate the role of monitoring CTCs in HNC50.
Figure 6. Patient “micro_01, micro_06”; CTC clusters detected in the blood. (a) 100x magnification 
showing the CTC cluster in the top of the cytospot. 1000x images of (b) DAPI (c) Cytokeratin/DAPI composite 
(d) DAPI (e) Cytokeratin (f) Cytokeratin/DAPI composite. Scale bar represents 50 μ m. Figure 6 continued. 
Patient “micro_12”; CTC doublet detected in blood. (g) DAPI (h) Cytokeratin/DAPI composite (i) EGFR/DAPI 
composite. Patient “micro_03” single CTCs detected in blood. (j) DAPI (k) Cytokeratin/DAPI composite (l) 
EGFR/DAPI composite. Scale bar 10 μ m (g–i). Scale bar 50 μ m (j–l).
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Figure 7. EGFR gene amplification in CTCs derived from head and neck cancer patients. Dual colour FISH 
assay probes for EGFR (red) and chromosome seven (CEP7, green). Row 1 shows individual stains for DAPI, 
CEP7, EGFR and the composite image (DAPI, CEP7, EGFR). Row 2 shows further patient CTC composite 
images showing EGFR amplification. Scale bar represents 10 μ m.
Figure 8. A FDG-PET study from a patient presenting with CTCs and had progressive disease to the lungs 
showing an 8 × 5 mm nodule in the left upper lobe. 
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Conclusion
We present the first study in HNCs using a microfluidics based approach for CTC enrichment. 24 HNC patient 
blood samples were enriched using the spiral microfluidics chip. We were able to identify single and clusters 
of CTCs and further characterise these cells by ICC and DNA FISH. This study highlights the use of the spiral 
microfluidic technology in HNC and provides future clinical use in the field of CTCs.
Materials and Methods
Patient cohort. Ethics approval was obtained from the Metro South and North Health Service District 
Human Research Ethics Committee in accordance with the National Health and Medical Research Council’s 
guidelines (HREC/12/PHAH381) to collect blood from the Royal Brisbane and Women’s Hospital (RBWH). 
All methods were performed in accordance with these ethical guidelines and regulations. This study also has 
Queensland University of Technology ethics approval (1400000617). After written informed consent was 
obtained from the participants, 10 mL blood samples were collected from patients presenting to the HNC clinic.
Cell lines and culture. The cell lines FaDu (ATCC-HTB43), CAL27 (ATCC-CRL2095), RPMI2650 
(ATCC-CCL30) were obtained from ATCC (Manassas, VA). UD-SCC9 HNC cells (ATCC-CRL1629) were a gen-
erous gift from A/Prof Nick Saunders (UQDI). The MDA-MB-468 breast cancer cells were originally from the 
ATCC transferred from the Lombardi Cancer Center and fluorescently tagged with pCherryN1, a modification 
of the Clonetech vector, kindly provided by Dr Alpha Yap, (UQ). Cells were cultured under standard conditions 
in humidified incubators at 37 °C, 5% CO2 in RPMI-1640-Glutamax (Life Technologies, Inc) supplemented with 
10% fetal bovine serum (FBS) and 1% Penicillin/Streptomycin (Pen/Strep).
3D cell culture (bioreactor). Cells were spun down to obtain cell pellets post-trypsinization. The cell pellets 
were resuspended in pre-warmed 1x Happy Cell media (Biocroi Ltd, Dublin, Ireland) supplemented with 10% 
FBS and 1% Pen/Strep. Optimal seeding densities for the bioreactors were determined by titrating cells from 
10,000–500 cells/ml. 1,500 cells/ml, resuspended in 1x Happy Cell media were layered over 2x Happy Cell media 
in the bioreactor. This gradient ensured that the cells remained in suspension over the incubation periods. The 
cells were incubated at 37 °C, 5% CO2 and imaged every 3 days. To collect the spheroids, the cell suspension was 
transferred to a 96 well format and an inactivation buffer was used to collapse the hydrogel matrix for 1 hour at 
37 °C.
Spiking of cell lines into bloods collected from normal healthy controls. Blood was collected from 
normal healthy volunteers in 10 mL EDTA (BD-Plymouth, UK) tubes. The cell lines used for spiking were labelled 
with CellTracker™ Green (Life Technologies) as per manufacturer’s instructions. The collected blood was spiked 
with clinically relevant numbers (10–150) of cells within 2 hours of collection. Cell lines for spiking were har-
vested by trypsinisation for 5 mins at 37 °C and washed in the culture media. The cell suspension was centrifuged 
at 300 × g for 5 mins, the supernatant removed and cells resuspended in PBS buffer. Cell counts were performed 
with the Countess II FL automated Cell counter (ThermoFisher Scientific). The appropriate spike-in volume of 
cells was added to the blood.
Preparation of blood sample for the spiral Chip. To reduce the cellular components passing through 
the spiral chip, an initial red blood cell (RBC) lysis was performed, which has been shown to have minimal effects 
on the recovered cells15. Briefly, RBC lysis buffer (Astral Scientifix) was added to the blood sample, after which 
cells were centrifuged and the pellet resuspended in 10 mL of sheath buffer (1xPBS, 2 mM EDTA, 0.5% BSA).
Setup and running of the spiral Chip. Tygon® tubing was inserted into the inlet/outlets of the spiral chip, 
and the inlet tubing connected to a syringe pump. The spiral chip was positioned and fixed onto a phase contrast 
microscope (Olympus IX71). The outlet tubing was connected to two sterile 15 mL collection BD Falcon tubes. 
An initial priming run was performed using the sheath buffer at a flow rate of 2.0 mL/min for 5 minutes. To test 
patient samples, the sample was loaded carefully into a 10 ml syringe (Terumo) and pumped through the spiral 
chip using the syringe pump at a flow rate of 1.7 mL/min for all experiments. The outputs were collected and spun 
down at 300× g for 5 mins.
Immunostaining. Prelabeling and immunocytochemistry (ICC) were used for the detection of spiked 
tumour cells and CTCs enriched by the spiral microfluidic chip. Enriched cells were cytospun onto a glass slide and 
CTCs identified by ICC using the CellSearch antibody cocktail (Cytokeratin/CD45/DAPI; Janssen Diagnostics). 
Cells were further characterised for cell surface EGFR using an anti-EGFR antibody (AY13, BioLegend, San 
Diego). Briefly, the cytospun sample was air dried overnight and incubated with a mixture of CellSearch rea-
gents (20 ul staining reagent, 20 μ l DAPI, 20 μ l permeabilization buffer, 20 ul fixation buffer in 120 μ l PBS). 
The slide was incubated for 1 hour at room temperature, washed 3 times in PBS, coverslipped and imaged 
under a fluorescent microscope. The CellSearch criteria for CTCs were used for CTC identification: intact, 
cytokeratin-positive, DAPI-positive, CD45-negative cells that were larger than 4 um were considered a CTC. Cells 
staining positive for CD45 and DAPI and negative for pan-cytokeratin were determined to be white blood cells.
DNA Fluorescence in situ hybridization. Cytospots were placed in pretreatment solution for 10 mins 
at 98 °C, and digested with pepsin for 5 mins at 37 °C in the Dako hybridiser. After dehydration through a 
graded ethanol series (70%, 85%, 96%), dual colour, dual target DNA FISH assays were done with EGFR/CEN-7 
FISH probe mix (DakoCytomation, Glostrup, Denmark). Cytospots were covered with 10 μ L probe solution, 
sealed with rubber sealant and placed in the Dako Hybridizer for denaturation (5 mins, 82 °C) and hybridisa-
tion (18 hours, 45 oC). Post hybridisation stringency washes were performed at 65 oC for 10 mins. After further 
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washing and dehydration steps, the cytospots were air dried and mounting media containing DAPI added. The 
cytospot was coverslipped and imaged on the Nikon Eclipse Ti inverted microscope fitted with a Nikon digital 
camera. EGFR was visualized as a red signal (tetramethylrhodamine isothiocyanate filter), CEP7 (fluorescein 
isothiocyanate filter) as a green signal and the nuclei as a blue signal with a DAPI filter. EGFR status was scored as 
the number of EGFR signals per nucleus and as the ratio of EGFR signals to CEP7 signals.
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